ClinicalTrials.gg
Not yet recruitingNCT07630038Updated Jun 5, 2026

HFNO Flow Rates and Cerebral Oxygenation During Deep Sedation for Cystoscopy

An interventional study of High-Flow Nasal Oxygen 40 L/min (HF40) and High-Flow Nasal Oxygen 55 L/min (HF55) in Deep Sedation, High Flow Nasal Canula and Cerebral Oxygenation, sponsored by Firat University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Firat University · Not applicable, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

For Patients and Families

This study aims to investigate how high-flow oxygen therapy affects oxygen levels, especially brain oxygenation, during cystoscopy procedures performed under sedation. The goal is to improve patient safety and comfort by ensuring better oxygen delivery during the procedure. Different oxygen flow rates will be compared, while patients' breathing, oxygen levels, and vital signs are continuously monitored throughout the procedure. All methods used in the study are consistent with routine anesthesia practices, and patient safety remains the highest priority.

For Healthcare Professionals

This prospective randomized controlled study evaluates the effects of different high-flow nasal oxygen (HFNO) flow rates on cerebral oxygenation, peripheral oxygenation, and ventilation parameters in patients undergoing cystoscopy under procedural sedation. The primary aim is to determine the contribution of HFNO to sedation safety and to provide clinical evidence regarding the optimal flow rate. In addition, hypoxemia incidence, airway intervention requirements, hemodynamic variables, and sedation depth are being analyzed.

02

Conditions studied

  • Deep Sedation
  • High Flow Nasal Canula
  • Cerebral Oxygenation
  • PSI

Keywords

  • High Flow Nasal Canula
  • Deep Sedation
  • rSO2
  • PSI
03

In context

Lead sponsor

Firat University is the lead sponsor of 119 studies on the registry; 45 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Scheduled to undergo elective cystoscopy under procedural sedation in an operating room setting
  • (ASA) physical status classification I-III
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Known neurological disorders
  • History of ischemic or hemorrhagic stroke
  • Peripheral artery disease
  • Vasculitis
  • Severe heart failure
  • Uncontrolled hypertension
  • Uncontrolled diabetes mellitus
  • Advanced-stage
  • Severe anemia ( \<8 g/dL)
  • Skin lesions that could interfere with near-infrared spectroscopy (NIRS) measurements
  • History of head trauma
  • History of cranial surgery
  • Nasal deformity or nasal obstruction
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    HF40

    Participants receive high-flow nasal oxygen (HFNO) therapy at a flow rate of 40 L/min during procedural sedation for cystoscopy.

    Device: High-Flow Nasal Oxygen 40 L/min (HF40)

  • Experimental
    HF55

    Participants receive HFNO therapy at a flow rate of 55 L/min during procedural sedation for cystoscopy.

    Device: High-Flow Nasal Oxygen 55 L/min (HF55)

  • Experimental
    HF70

    Participants receive HFNO therapy at a flow rate of 70 L/min during procedural sedation for cystoscopy.

    Device: High-Flow Nasal Oxygen 70 L/min (HF70)

Interventions

  • DeviceHigh-Flow Nasal Oxygen 40 L/min (HF40)

    Participants receive high-flow nasal oxygen (HFNO) therapy delivered through the OptiFlow™ system at a flow rate of 40 L/min with 100% heated and humidified oxygen during procedural sedation for cystoscopy. Sedation is achieved using midazolam, remifentanil, and propofol.

  • DeviceHigh-Flow Nasal Oxygen 55 L/min (HF55)

    Participants receive HFNO therapy via the OptiFlow™ system at a flow rate of 55 L/min with 100% heated and humidified oxygen during procedural sedation for cystoscopy, together with the same standardized sedation protocol.

  • DeviceHigh-Flow Nasal Oxygen 70 L/min (HF70)

    Participants receive HFNO therapy via the OptiFlow™ system at a flow rate of 70 L/min with 100% heated and humidified oxygen during procedural sedation for cystoscopy, together with the same standardized sedation protocol.

06

What researchers measure

Primary outcomes

  1. Change in Regional Cerebral Oxygen Saturation (rSO₂)

    Unit: %. Regional cerebral oxygen saturation values measured by near-infrared spectroscopy (NIRS) during procedural sedation will be compared among the three HFNO flow rate groups to evaluate the effect of different HFNO flow rates on cerebral oxygenation.

    Time frame: From baseline measurement before sedation until the end of the cystoscopy procedure (intraoperative period). Cerebral oxygen saturation (rSO₂) values are recorded continuously during procedural sedation.

Secondary outcomes

  1. Peripheral Oxygen Saturation (SpO₂)

    Unit: % . Evaluation of peripheral oxygenation levels during procedural sedation.

    Time frame: From baseline measurement before sedation until the end of the cystoscopy procedure (intraoperative period). Cerebral oxygen saturation (rSO₂) values are recorded continuously during procedural sedation.

  2. Partial arterial carbon dioxide pressure (PaCO₂)

    Unit: mmHg. Assessment of arterial carbon dioxide pressure levels during sedation.

    Time frame: At baseline before the initiation of sedation and at the end of the cystoscopy procedure. Arterial blood gas analysis (PaCO₂) and end-tidal carbon dioxide (EtCO₂) measurements will be recorded at both time points.

  3. End-tidal carbon dioxide (EtCO₂)

    Unit: mmHg. Assessment of end-tidal carbon dioxide levels during sedation.

    Time frame: At baseline before the initiation of sedation and at the end of the cystoscopy procedure. End-tidal carbon dioxide (EtCO₂) measurements will be recorded at both time points.

  4. Incidence of Hypoxemia

    Frequency of hypoxemia episodes defined as SpO₂ \<90% or \>20% decrease in rSO₂ from baseline.

    Time frame: From the initiation of procedural sedation until the end of the cystoscopy procedure. Hypoxemia episodes occurring during the intraoperative sedation period will be recorded continuously.

  5. Airway Intervention Requirement

    Need for airway maneuvers or ventilatory support during the procedure.

    Time frame: From the initiation of procedural sedation until the end of the cystoscopy procedure. Any airway intervention requirement occurring during the intraoperative period will be recorded.

  6. Heart Rate

    Unit: beats/min. Changes in heart rate during procedural sedation.

    Time frame: From baseline before sedation until the end of the cystoscopy procedure. Heart rate will be recorded continuously during the intraoperative sedation period.

  7. Mean Arterial Pressure

    Unit: mmHg. Changes in blood pressure during procedural sedation.

    Time frame: From baseline before sedation until the end of the cystoscopy procedure. Blood pressure, will be recorded continuously during the intraoperative sedation period.

  8. Patient State Index (PSI)

    Unit of Measure: score. Sedation depth will be continuously monitored intraoperatively using Patient State Index (PSI), a numerical electroencephalography-derived index ranging from 0 to 100, where lower values indicate deeper levels of sedation.

    Time frame: From the initiation of sedation until the end of the cystoscopy procedure.

  9. Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score

    Unit of Measure: score. Sedation depth will be assessed intraoperatively using the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale, an ordinal sedation scale ranging from 0 to 5, where lower scores indicate deeper levels of sedation.

    Time frame: From the initiation of sedation until the end of the cystoscopy procedure.

  10. Patient Satisfaction

    Postoperative patient satisfaction following cystoscopy under procedural sedation will be assessed using a 5-point Likert satisfaction scale, where higher scores indicate greater patient satisfaction.

    Time frame: Assessed once at the end of the recovery period immediately after completion of the cystoscopy procedure (postoperative period, approximately 30-60 minutes after the procedure).

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared due to patient confidentiality, privacy concerns, and institutional ethical regulations. Data may be made available from the corresponding author upon reasonable request and with ethics committee approval

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Sep 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
Jun 5, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Sep 1, 2026
CompletionEst.
Oct 1, 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07630038
Lead sponsor
Firat University
Responsible party
AHMET AKSU (Assistant Professor, Firat University) — Principal investigator
First posted
Jun 5, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Sep 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Jun 5, 2026

Study contacts

Ahmet Aksu, Assistant Professor
Contact
drahmetaksu@gmail.com
+905303493896

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion